Total Funding
12
Total FundingSeries A raised
Growth Score
pts
Heat Score
10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
ApcinteX develops and markets anticoagulant APC pathway to treat haemophilia.
- Jo Davies: IP Manager
Jim Huntington: CEOPast Role: XO1, Co-Founder and Co-Chair
About the Company
ApcinteX develops and markets anticoagulant APC pathway to treat haemophilia. Apcintex has developed a new treatment that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia. This means that the drug could potentially treat patients with all types of haemophilia,
including those who develop antibodies to replacement factors. Furthermore, the drug does not cause anti-clotting antibodies to form and could be administered fortnightly by simple injection under the skin.
